Compare PPT & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPT | IPSC |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.3M | 268.0M |
| IPO Year | N/A | 2021 |
| Metric | PPT | IPSC |
|---|---|---|
| Price | $3.22 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 138.4K | ★ 722.8K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 8.84% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $3.21 | $0.44 |
| 52 Week High | $3.67 | $2.97 |
| Indicator | PPT | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 41.24 |
| Support Level | N/A | $1.22 |
| Resistance Level | $3.32 | $2.62 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 29.33 | 55.09 |
Putnam Premier Income Trust is a closed-end fixed income fund that prominently invests in U.S. government, agency, high-yield, and international fixed income securities. The fund aims to provide high current income while preserving capital by diversifying across multiple bond markets beyond traditional benchmarks. Its portfolio includes various sectors such as investment-grade and high-yield corporate bonds, mortgage-backed securities, bank loans, and emerging market debt. Revenue for the trust is generated through interest income and capital gains from its investments in a fixed fund, which operates on the New York Stock Exchange and focuses on managing a diverse range of fixed-income assets across various countries.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.